Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Sedative-Hypnotic

or Tryptamine

or [[:Category:Progestins|Progestin (synthetic progestogen)]]

Use the filters below to narrow your results.

None (2) · 5-HT2A agonist (15) · 5-HT2A agonist; 5-HT3 antagonist (1) · 5-HT2A agonist; minor psilocybin mushroom alkaloid (1) · 5-HT2A agonist; primarily auditory effects (1) · 5-HT2A agonist; sigma-1 agonist (1) · Extremely potent GABAA positive allosteric modulator (1) · GABAA positive allosteric modulator (15) · GABAA positive allosteric modulator (non-benzodiazepine) (3) · GABAA positive allosteric modulator; very long half-life (1) · GABAA potentiator (1) · GABAA potentiator and direct activator (2) · GABAB agonist; GHB receptor agonist (1) · Melatonin receptor agonist (2) · Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor (1) · Positive allosteric modulator of the GABAA receptor at the benzodiazepine binding site; increases frequency of Cl− channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) · Potent 5-HT2A agonist; sigma-1 agonist (1) · Prodrug of 4-HO-DET; 5-HT2A agonist (1) · Prodrug of 4-HO-DiPT; 5-HT2A agonist (1) · Prodrug of 4-HO-MET; 5-HT2A agonist (1) · Prodrug of 4-HO-MiPT; 5-HT2A agonist (1) · Prodrug of psilocin; 5-HT2A agonist (1) · Selective GABAA agonist (extrasynaptic delta subunit) (1) · '"`UNIQ--vote-000013EE-QINU`"' Higher-dose Aygestin (5 mg) achieves more reliable ovulation suppression and is used for endometriosis and DUB. POP requires strict daily timing because the 24-hour cervical-mucus effect window is narrower than COC'"`UNIQ--ref-000013EF-QINU`"'. (1)

None (55) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) · '"`UNIQ--vote-000013F0-QINU`"', '"`UNIQ--vote-000013F1-QINU`"', '"`UNIQ--vote-000013F2-QINU`"', '"`UNIQ--vote-000013F3-QINU`"', '"`UNIQ--vote-000013F4-QINU`"' (1)

None (55) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1) · POP: 0.35 mg PO daily continuously (no placebo week); high-dose 5 mg Aygestin for amenorrhea/endometriosis 5-10 mg/d (1)

None (55) · 0.35 mg POP tablets; 5 mg tablets (Aygestin); component of COCs and combination HRT (1) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)

None (55) · Indication-specific (1) · N/A (never approved) (1)

None (55) · intranasal; rectal and IV reported. (1) · Oral (2) · sublingual (1)

None (55) · Contraception within 48 hours of starting (POP); endometrial effects days (1) · ~20–40 min PO; faster sublingual/intranasal. (1)

None (55) · 6–10 h subjective; full pharmacologic effect considerably longer. (1) · ~24 hours per dose (strict timing required for POP — within 3-hour window each day) (1)

None (55) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) · ~8 hours'"`UNIQ--ref-000013F5-QINU`"' (1)

None (55) · Not formally characterized in humans. (1) · ~65% (oral)'"`UNIQ--ref-000013F6-QINU`"' (1)

None (55) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Contraindicated in known pregnancy (Aygestin); the 0.35 mg POP is not teratogenic and does not need to be discontinued before conception planning.[[[Pharmacopedia:Citation needed|citation needed]]] (1)

None (56) · [[USLegal:Prescription only|Rx-only]] in US (note: norgestrel 0.075 mg POP is now OTC as Opill since 2023, but norethindrone POP remains Rx) (1)

4

5

A

B

C

D

E

F

G

L

M

N

P

Q

R

S

T

Z